Liposomes can be seen as ideal carriers for anti-inflammatory drugs as their ability to
(passively) target sites of inflammation and release their content to inflammatory target cells …

Goal of the review While transplant recipients are aware of increased malignancy risk, there
is little consensus on the preventative measures. The goal of this review is to bring available …

Post-transplant lymphoproliferative disorders (PTLD) is a devastating complication of kidney
transplantation with an insidious presentation and potential to disseminate aggressively …

We describe the epidemiology of cancer after kidney transplantation (KTx), investigating its
risk factors and impact on therapeutic management and survival in KTx recipients (KTRs) …

Posttransplant lymphoproliferative disorder (PTLD) poses a significant concern in Epstein-
Barr virus (EBV)–negative patients transplanted from EBV-positive donors (EBV R-/D+) …

Kidney transplant recipients (KTRs) are at increased risk of developing de novo
posttransplant malignancies (PTMs) with regional differences in types with excessive risk …

Introduction The aim of this study is to assess the outcomes of different induction therapies
among mild to moderate immunological risk kidney transplants in the era tacrolimus and …

Posttransplant lymphoproliferative disorder (PTLD) occurs in 1% to 3% of adult renal
transplant recipients (RTRs). PTLD has a heterogeneous presentation and is often …

Background: Treatment with antithymocyte globulin (ATG) is a well-recognized risk factor for
the development of post-transplant lymphoproliferative disorders (PTLD) after solid organ …

Dear Editors, We have carefully read the study published by Ali et al. on the correlation
between rabbit anti-thymocyte globulin (r-ATG) and the development of post-transplant …